A Revolutionizing Obesity Drug: Is it the Future?

Highlights:

  • Transformative Obesity Drugs: Semaglutide and tirzepatide offer remarkable outcomes in weight loss, representing a new generation of medications for obesity.
  • Personalized Treatment Approach: Tailoring the treatment to each individual’s needs maximizes the benefits of these drugs.
  • Effective for “Hungry Gut” Phenotype: Individuals with frequent hunger between meals (the “hungry gut” phenotype) respond particularly well to semaglutide and tirzepatide.
  • Long-Term Usage for Sustained Results: Long-term usage is recommended to maintain weight loss, as discontinuation often leads to weight regain.
  • Balancing Weight Loss and Health: Striking the right balance is important, focusing on overall health improvements rather than solely pursuing maximum weight loss.

In recent years, a new generation of drugs has emerged, offering hope and transformative outcomes in the battle against obesity. These medications, including semaglutide and tirzepatide, have astounded researchers with their remarkable effectiveness in aiding weight loss. With semaglutide enabling one-third of participants in clinical trials to shed a staggering 20% of their body weight, and tirzepatide achieving similar results in over half of study participants, the potential impact of these drugs is undeniable.

Tailoring Treatment to Individuals

While the success stories surrounding semaglutide and tirzepatide are compelling, it is crucial to recognize that these drugs may not provide a universal solution for every individual grappling with obesity. Dr. Andres Acosta, an obesity specialist at the Mayo Clinic in Rochester, Minnesota, emphasizes that not everyone responds to these medications. As the prevalence of drugs like semaglutide and tirzepatide increases, healthcare providers have begun to unravel the factors that determine who can benefit most from their use while acknowledging the challenges they present.

Understanding the Mechanism of Action: Unleashing the Power of GLP-1

Semaglutide and tirzepatide function by mimicking a hormone known as glucagon-like peptide 1 (GLP-1), which plays a significant role in appetite regulation. In 2021, the US Food and Drug Administration approved semaglutide, marketed as Wegovy, for the treatment of obesity. Although tirzepatide, known as Mounjaro, received approval in 2022 exclusively for type 2 diabetes treatment, it is often prescribed as a weight-loss agent.

Tailoring Treatment to Individuals: A Personalized Approach

Researchers have observed that an individual’s response to these medications depends on the underlying cause of their obesity. Dr. Acosta and his team at the Mayo Clinic have developed a method to customize the treatment to each person’s specific needs. The team has classified people with obesity into four subtypes: “hungry brain,” “hungry gut,” “emotional hunger,” and “slow burn.”

Tailoring Treatment to Individuals: Unveiling the Phenotype Connection

People with a “hungry gut” phenotype, characterized by frequent hunger between meals, appear to respond particularly well to the new drugs, as observed anecdotally by Dr. Acosta and his team. Although the exact reason remains unclear, Dr. Acosta proposes a hypothesis: these patients may have low levels of GLP-1 hormones, which contribute to their obesity. By providing them with GLP-1 analogues like semaglutide and tirzepatide, significant improvements can be achieved.

Enhancing Fullness and Flexibility

Dr. Beverly Tchang, an endocrinologist at Weill Cornell Medicine in New York City, agrees with Dr. Acosta’s classification based on her anecdotal experience. She acknowledges that individuals with the “hungry-gut” phenotype tend to respond favorably to GLP-1-mimicking drugs. Furthermore, data from other research groups support Dr. Acosta’s hypothesis. Semaglutide, in particular, has been shown to slow down gut movement and improve the sensation of fullness.

In addition to their effectiveness, semaglutide and tirzepatide offer benefits in terms of flexibility. Their weekly regimen accommodates individuals with erratic schedules and varying work shifts, addressing the challenges posed by other medications that require specific timing.

Determining Long-Term Use: Sustaining Progress

Researchers are not only interested in identifying who will benefit most from these medications but also understanding the ideal duration of treatment. A clinical trial revealed that participants who discontinued semaglutide after 20 weeks regained most of their initial weight loss, while those who continued the medication sustained their progress. Recognizing obesity as a chronic condition, Dr. Acosta recommends long-term usage of these medications. However, further investigation is required to determine the exact duration and potential lifelong usage.

Balancing Weight Loss and Health: Striking the Right Balance

Another challenge arises when determining the appropriate extent of weight loss achieved through these drugs. Dr. Tchang highlights their incredible effectiveness, to the point where practitioners are now considering how much weight loss is too much. Excessive weight loss can lead to muscle and fat reduction, heightening the risk of cardiovascular disease, osteoporosis, and other disorders, which is particularly concerning for older individuals and those with pre-existing cardiovascular conditions. This issue is related to the “obesity paradox,” where weight loss correlates with a higher mortality rate.

To strike a balance, healthcare providers are increasingly focusing on addressing obesity-related problems, such as sleep apnea, fatty liver disease, and type 2 diabetes, rather than fixating solely on significant weight reduction. Specialists like Dr. Tchang are exploring the potential of prescribing lower doses to achieve this objective. Treating individuals for their overall health, disease prevention, and improved quality of life is paramount, rather than solely pursuing maximum weight loss.

Conclusion: A New Era in Obesity Treatment

The emergence of semaglutide and tirzepatide represents a significant milestone in the treatment of obesity. These game-changing drugs demonstrate remarkable effectiveness, offering hope to millions of individuals worldwide struggling with weight management. By tailoring treatment to individuals’ needs, identifying the most suitable candidates for these medications, and considering long-term usage, researchers and healthcare professionals aim to optimize the benefits while mitigating potential risks. As further studies unfold, advancements in precision medicine could revolutionize the way we combat the obesity epidemic, improving health outcomes, and enhancing the quality of life for countless individuals.

More News : 

Pentagon Explosion Hoax

“Killers of The Flower Moon” Premiere at Cannes Receives Standing Ovation

G7 Summit Concludes, Biden’s compares crypto traders to “wealthy tax evaders”

Stray Dog Takes Local Train Everyday For Commute, Internet loves it.

Child Screams for 8 hours straight on a Flight. Watch Video

India’s Ambitious Space Project: Unmanned Mission and Female Robot to Precede Gaganyaan Human Space-Flight Programme

References:

  1. Acosta, A. et al. Obesity 29, 662–671 (2021).Article PubMed Google Scholar 
  2. Jensterle, M. et al. Endocr. Abstr. 81, OC5.2 (2022).Article Google Scholar 
  3. Rubino, D. et al. JAMA 325, 1414–1425 (2021).Article PubMed Google Scholar
Techy
Techy

Techy is a versatile and prolific author known for his expertise in writing articles on a wide range of topics.

Articles: 37